Cyteir Therapeutics Inc Quick Ratio (CYT) starting from the third quarter 2023 to third quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Cyteir Therapeutics Inc   (NASDAQ: CYT)

Cyteir Therapeutics Inc 's Quick Ratio

CYT's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Current Liabilities decreased faster than Cyteir Therapeutics Inc 's Cash & cash equivalent, this led to improvement in Cyteir Therapeutics Inc 's Quick Ratio to 21.65, above Cyteir Therapeutics Inc average Quick Ratio.

Within Major Pharmaceutical Preparations industry 29 other companies have achieved higher Quick Ratio than Cyteir Therapeutics Inc in third quarter 2023. While Quick Ratio total ranking has improved so far during the Q3 2023 to 129, from total ranking in the second quarter 2023 at 136.

Explain Quick Ratio?
How much Cash & cash equivalents CYT´s has?
What are CYT´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CYT Quick Ratio (Sep 30 2023)
Q3		 (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3
Y / Y Current Liabilities Change 2.63 % -22.65 % -56.73 % -29.24 % -22.76 %
Y / Y Cash & cash equivalent Change -16.02 % -19.69 % -22.65 % -22.46 % -22.99 %
Quick Ratio MRQ 21.65 20.31 34.64 27.68 26.46
CYT's Total Ranking # 129 # 136 # 49 # 103 # 131
Seq. Current Liabilities Change -9.27 % 66.09 % -25.48 % -8.61 % -31.62 %
Seq. Cash & cash equivalent Change -3.29 % -2.6 % -6.74 % -4.4 % -7.52 %



Quick Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 30
Healthcare Sector # 44
Overall Market # 129


Quick Ratio Statistics
High Average Low
34.64 10.22 0.22
(Mar 31 2023)   (Dec 31 2012)




Financial Statements
Cyteir Therapeutics Inc 's Current Liabilities $ 6 Millions Visit CYT's Balance sheet
Cyteir Therapeutics Inc 's Cash & cash equivalent $ 129 Millions Visit CYT's Balance sheet
Source of CYT's Sales Visit CYT's Sales by Geography


Cumulative Cyteir Therapeutics Inc 's Quick Ratio

CYT's Quick Ratio for the trailling 12 Months

CYT Quick Ratio

 (Sep 30 2023)
12 Months		 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months
Y / Y Current Liabilities TTM Growth -29.57 % -33.73 % -25.41 % 11.84 % -91.6 %
Y / Y Cash & cash equivalent TTM Growth -20.39 % -22.02 % -21.02 % 7.62 % 18.46 %
Quick Ratio TTM 25.07 26.39 25.62 22.4 22.18
Total Ranking TTM # 2639 # 2113 # 2612 # 3212 # 2727
Seq. Current Liabilities TTM Growth 0.71 % -8.17 % -18.04 % -7.09 % -5.24 %
Seq. Cash & cash equivalent TTM Growth -4.31 % -5.42 % -6.23 % -6.2 % -6.26 %

Quick ratio ranking by company, industry and sector >> Back to CYT Financial Strength Comparisons >> Go to Compare CYT Quick Ratio to its Competitors

On the trailing twelve months basis Due to decrease in Current Liabilities in the Q3 2023 to $5.97 millions, cumulative Quick Ratio decreased to 25.07 above the CYT average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 476 other companies have achieved higher Quick Ratio than Cyteir Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2023 from 2113 to 2639.

Explain Quick Ratio?
How much Cash & cash equivalents CYT´s has?
What are CYT´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 477
Healthcare Sector # 919
Within the Market # 2639


trailing twelve months Quick Ratio Statistics
High Average Low
26.39 7.46 0.35
(Jun 30 2023)   (Sep 30 2013)




Companies with similar Quick Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2023 MRQ Cash & cash equivalentSep 30 2023 MRQ Current Liabilities
Moonlake Immunotherapeutics  48.12 $ 495.979  Millions$ 10.308  Millions
Third Harmonic Bio Inc   46.52 $ 273.892  Millions$ 5.888  Millions
Altimmune inc   46.22 $ 140.779  Millions$ 3.046  Millions
Neurogene Inc   42.92 $ 156.999  Millions$ 3.658  Millions
Arca Biopharma Inc  38.80 $ 38.487  Millions$ 0.992  Millions
Nuvation Bio Inc   38.37 $ 619.339  Millions$ 16.143  Millions
Merrimack Pharmaceuticals Inc  38.34 $ 18.904  Millions$ 0.493  Millions
Xbiotech Inc   38.19 $ 202.191  Millions$ 5.294  Millions
Morphic Holding inc   37.57 $ 725.067  Millions$ 19.298  Millions
Climb Bio Inc   37.03 $ 107.433  Millions$ 2.901  Millions
Royalty Pharma Plc  35.91 $ 941.748  Millions$ 26.222  Millions
Adc Therapeutics Sa  34.58 $ 310.407  Millions$ 8.977  Millions
Rayzebio Inc   34.09 $ 540.169  Millions$ 15.847  Millions
Cymabay Therapeutics Inc   31.72 $ 438.778  Millions$ 13.831  Millions
Atea Pharmaceuticals Inc   31.50 $ 595.126  Millions$ 18.893  Millions
Greenwich Lifesciences Inc   30.76 $ 9.144  Millions$ 0.297  Millions
Verona Pharma Plc  29.80 $ 257.366  Millions$ 8.636  Millions
Aprea Therapeutics Inc   29.39 $ 25.354  Millions$ 0.863  Millions
Theseus Pharmaceuticals Inc   29.29 $ 205.122  Millions$ 7.003  Millions
Viking Therapeutics Inc   28.75 $ 376.241  Millions$ 13.086  Millions
Karuna Therapeutics Inc   27.40 $ 1,341.510  Millions$ 48.968  Millions
Atossa Therapeutics Inc   27.33 $ 94.141  Millions$ 3.444  Millions
Disc Medicine Inc   25.70 $ 370.541  Millions$ 14.416  Millions
Belite Bio Inc  24.27 $ 88.157  Millions$ 3.633  Millions
Janux Therapeutics Inc   24.17 $ 349.712  Millions$ 14.471  Millions
Bright Minds Biosciences Inc   24.16 $ 5.197  Millions$ 0.215  Millions
Design Therapeutics Inc   23.48 $ 290.940  Millions$ 12.390  Millions
Lixte Biotechnology Holdings Inc   23.08 $ 5.106  Millions$ 0.221  Millions
Anixa Biosciences Inc   23.06 $ 46.773  Millions$ 2.028  Millions
Diamedica Therapeutics Inc   22.23 $ 46.465  Millions$ 2.090  Millions

Date modified: 2026-09-26T07:39:43+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.